Skip to main content
Clinical Trials/NCT02557477
NCT02557477
Completed
Not Applicable

Omega 3/6 Fatty Acids for Reading in Children: A Randomised, Double-blind, Placebo-controlled Trial in 9-year-old Mainstream Schoolchildren in Sweden

Göteborg University0 sites154 target enrollmentMarch 2010
ConditionsReading Ability

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Reading Ability
Sponsor
Göteborg University
Enrollment
154
Primary Endpoint
Change in reading ability
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

The primary objective was to assess whether supplementation of Omega 3/6 fatty acids improves mainstream schoolchildren's reading ability. The secondary objective was to assess whether Omega 3/6 improves cognitive functions such as attention, memory, learning, language/communication, problem solving and social ability.This was a 3-month randomised, double-blind, placebo-controlled study followed by one-way crossover (placebo to active treatment) for an additional 3 months. Mainstream schoolchildren aged 9-10 years were initially randomised to receive three Omega 3/6 capsules twice daily or identical placebo. All outcome measures were assessed at baseline, 3 months and 6 months. The primary outcome measure was the LOGOS test, a comprehensive test battery for evaluating reading abilities. Secondary outcome measures were the parent-rated Attention Deficit Hyperactivity Disorder (ADHD) Rating Scale-IV, 5-15 scale (domains of learning, memory, language/communication and problem solving); Social and Communication Disorders Checklist (to evaluate social ability)

Detailed Description

This was a 3-month randomized, double-blind, placebo-controlled study (Period 1) followed by one-way crossover (placebo to active treatment) for an additional 3 months (Period 2). Participants were randomized to receive three Omega 3/6 capsules twice daily (corresponding to a daily dose of 558 mg EPA, 174 mg DHA, and 60 mg gamma-linolenic acid) or identical placebo capsules (palm oil). All daily doses were taken at home supervised by the parents. All outcome measures were assessed at baseline and at the 3- and 6-month follow-up visits. The participants were mainstream schoolchildren in the 3rd school year (aged 9-10 years). Exclusion criteria were continuous supplementation of Omega-3 fatty acids for periods longer than 1 month during the previous year, significant medical conditions (e.g. diabetes, epilepsy), intellectual disability, attention-deficit hyperactivity disorder (ADHD) diagnosis, psychoactive medication, or substance use.

Registry
clinicaltrials.gov
Start Date
March 2010
End Date
December 2012
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Göteborg University
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • mainstream schoolchildren in the 3rd school year (aged 9-10 years).

Exclusion Criteria

  • continuous supplementation of Omega-3 fatty acids for periods longer than 1 month during the previous year
  • significant medical conditions (e.g. diabetes, epilepsy)
  • intellectual disability
  • attention-deficit hyperactivity disorder (ADHD) diagnosis, psychoactive medication, or substance use.

Outcomes

Primary Outcomes

Change in reading ability

Time Frame: 0, 3 and 6 months

LOGOS test: Computerized test of several functions implicated in reading ability

Secondary Outcomes

  • Change in ADHD symptom severity(0, 3 and 6 months)
  • Change in learning ability(0,3 and 6 months)
  • Change in memory ability(0, 3 and 6 months)
  • Change in language/communication ability(0,3 and 6 months)
  • Change in problem solving ability(0,3 and 6 months)
  • Change in social ability(0,3 and 6 months)

Similar Trials